- Home
- RRR vs AKRO Comparison
RRR vs AKRO Comparison
Compare RRR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRR
- AKRO
- Stock Information
- Founded
- RRR 1976
- AKRO 2017
- Country
- RRR United States
- AKRO United States
- Employees
- RRR N/A
- AKRO 67
- Industry
- RRR Hotels/Resorts
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- RRR Consumer Discretionary
- AKRO Health Care
- Exchange
- RRR Nasdaq
- AKRO Nasdaq
- Market Cap
- RRR 3.5B
- AKRO 4.5B
- IPO Year
- RRR 2016
- AKRO 2019
- Fundamental
- Price
- RRR $57.26
- AKRO $54.31
- Analyst Decision
- RRR Buy
- AKRO Buy
- Analyst Count
- RRR 13
- AKRO 10
- Target Price
- RRR $61.54
- AKRO $73.56
- AVG Volume (30 Days)
- RRR 1.3M
- AKRO 1.7M
- Earning Date
- RRR 10-28-2025
- AKRO 11-07-2025
- Dividend Yield
- RRR 3.56%
- AKRO N/A
- EPS Growth
- RRR 15.51
- AKRO N/A
- EPS
- RRR 3.14
- AKRO N/A
- Revenue
- RRR $1,995,401,000.00
- AKRO N/A
- Revenue This Year
- RRR $4.18
- AKRO N/A
- Revenue Next Year
- RRR $3.27
- AKRO N/A
- P/E Ratio
- RRR $18.29
- AKRO N/A
- Revenue Growth
- RRR 4.69
- AKRO N/A
- 52 Week Low
- RRR $35.09
- AKRO $21.34
- 52 Week High
- RRR $63.60
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- RRR 49.32
- AKRO 68.45
- Support Level
- RRR $53.35
- AKRO $53.90
- Resistance Level
- RRR $59.71
- AKRO $54.37
- Average True Range (ATR)
- RRR 1.91
- AKRO 0.20
- MACD
- RRR 0.39
- AKRO -0.23
- Stochastic Oscillator
- RRR 67.06
- AKRO 87.20
About RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.